Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)WithdrawnNCT04465734
What this trial is testing

A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

Who this might be right for
Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech
Large-scale testing (Phase 3)UnknownNCT05737563
What this trial is testing

PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC

Who this might be right for
Esophageal Squamous Cell Carcinoma Abdominal Stage 0
Sun Yat-sen University 380
Testing effectiveness (Phase 2)UnknownNCT04620837
What this trial is testing

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Who this might be right for
Small Cell Lung Carcinoma
Chinese Academy of Medical Sciences 25
Large-scale testing (Phase 3)Study completedNCT04205812
What this trial is testing

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Squamous Non-Small Cell Lung CancerMetastatic Nonsquamous Non-Small Cell Lung Cancer
Incyte Corporation 583
Large-scale testing (Phase 3)Study completedNCT02504372
What this trial is testing

Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 1,177
Large-scale testing (Phase 3)Study completedNCT03358875
What this trial is testing

Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
BeiGene 805
Early research (Phase 1)Active Not RecruitingNCT06377111
What this trial is testing

Test the Benefit of Vitamin B5 in Patients With Melanoma

Who this might be right for
Melanoma (Skin)
University Health Network, Toronto 12
Testing effectiveness (Phase 2)Study completedNCT03190811
What this trial is testing

Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors

Who this might be right for
Neoplasms
Capital Medical University 100
Early research (Phase 1)Ended earlyNCT06580938
What this trial is testing

Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

Who this might be right for
Non Small Cell Lung CancerBladder CancerRenal Cell Carcinoma+3 more
Pfizer 4
Testing effectiveness (Phase 2)Looking for participantsNCT06437509
What this trial is testing

BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

Who this might be right for
Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 66
Testing effectiveness (Phase 2)Study completedNCT04669899
What this trial is testing

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Who this might be right for
Cancer
Jounce Therapeutics, Inc. 190
Not applicableUnknownNCT06335147
What this trial is testing

PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer

Who this might be right for
Metastatic Colon Cancer
Henan Cancer Hospital 23
Not applicableUnknownNCT04944511
What this trial is testing

PD-1 Antibody Improve Mixed Chimerism

Who this might be right for
PD-1 AntibodyMixed Chimerism
Beijing Friendship Hospital 20
Early research (Phase 1)Study completedNCT05332704
What this trial is testing

Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685

Who this might be right for
Plaque Psoriasis
Ono Pharmaceutical Co., Ltd. 33
Early research (Phase 1)UnknownNCT06404281
What this trial is testing

Γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Changzhou No.2 People's Hospital 9
Testing effectiveness (Phase 2)Study completedNCT03453164
What this trial is testing

Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)

Who this might be right for
Gastric Cancer
Fukushima Medical University 41
Testing effectiveness (Phase 2)UnknownNCT02862028
What this trial is testing

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

Who this might be right for
PD-1 AntibodyCAR-T CellsAdvanced Solid Tumor
Shanghai International Medical Center 20
Testing effectiveness (Phase 2)Looking for participantsNCT06556199
What this trial is testing

Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

Who this might be right for
Relapsed/Refractory Primary Central Nervous System Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine 38
Testing effectiveness (Phase 2)Study completedNCT03171064
What this trial is testing

Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment

Who this might be right for
PD-1 AntibodiesExerciseMelanoma
University Hospital Heidelberg 39
Testing effectiveness (Phase 2)Active Not RecruitingNCT04214249
What this trial is testing

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+1 more
National Cancer Institute (NCI)
Next Page
49